Meeting
2023 ASCO Annual Meeting
Cerebrospinal fluid immunological cytokines to predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases: GASTO 1060.
Authors
Likun Chen
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Likun Chen , Meichen Li , Jing Chen , Hui Yu , Baishen Zhang , Xue Hou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2040)
DOI
10.1200/JCO.2023.41.16_suppl.2040
Abstract #
2040
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance.
First Author: Jiefei Han
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
First Author: David S. Hong
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
First Author: C. Marcela Diaz-Montero
Poster
2017 ASCO Annual Meeting
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
First Author: Anders Mellemgaard